Published in AIDS Vaccine Week, January 17th, 2005
The phase I study evaluated multiple dosing regimens of the CEA-TRICOM vaccines in 58 patients with advanced CEA-expressing tumors. Investigators found that disease stabilization was achieved for at least 4 months in 40% of the study participants, and for more than 6 months in 24% of the participants.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.